Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
about
Free-water and BOLD imaging changes in Parkinson's disease patients chronically treated with a MAO-B inhibitor.Controversies in neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.Multi criteria decision making to select the best method for the preparation of solid lipid nanoparticles of rasagiline mesylate using analytic hierarchy process.Priority setting partnership to identify the top 10 research priorities for the management of Parkinson's diseaseHydralazine is involved in tele-methylhistamine metabolism by inhibiting monoamine oxidase B in pregnancy-associated hypertensive mice.L-dopa-induced dopamine synthesis and oxidative stress in serotonergic cellsInterplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neuronsClinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type-B inhibitor: A Cross-Sectional, Cohort StudyMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?Pharmacologic safety concerns in Parkinson's disease: facts and insights.Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors.Potential food-drug interactions in patients with rheumatoid arthritis.Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Improving L-dopa therapy: the development of enzyme inhibitors.Recent trends in the transdermal delivery of therapeutic agents used for the management of neurodegenerative diseases.Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells.Rasagiline-induced severe recurrent hypoglycemia in a young woman without diabetes: a case reportClinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective Potential.Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.Nasal in-situ gels for delivery of rasagiline mesylate: improvement in bioavailability and brain localization.Liquid chromatographic resolution of racemic rasagiline and its analogues on a chiral stationary phase based on (+)-(18-crown-6)-2,3,11,12-tetracarboxylic acid.2,2'-Dithienyl diselenide, an organoselenium compound, elicits antioxidant action and inhibits monoamine oxidase activity in vitro.Computer-aided drug design applied to Parkinson targets.Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO).Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease.The antidepressant tranylcypromine alters cellular proliferation and migration in the adult goldfish brain.Synthesis and pharmacological evaluation of donepezil-based agents as new cholinesterase/monoamine oxidase inhibitors for the potential application against Alzheimer's disease.Strategies to maintain quality of life among people with Parkinson's disease: what works?Impregnated copper on magnetite: an efficient and green catalyst for the multicomponent preparation of propargylamines under solvent free conditions.Large differences in levodopa dose requirement in Parkinson's disease: men use higher doses than women.Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson's diseaseSynthesis of 3-(Alk-2-yn-1-yl)-1,3-Oxazolidines Using Copper-Containing CatalystsDevelopment and Validation of a Stability-Indicating HPTLC Method for Analysis of Rasagiline Mesylate in the Bulk Drug and Tablet Dosage FormDevelopment and Validation of Spectrophotometric Methods for the Determination of Rasagiline in Pharmaceutical Preparations
P2860
Q31080092-228B94C0-B050-4380-BCBE-F34DC7F988E0Q34027880-5CFCF2D2-B38D-4FE3-8DFC-908DF5FA6382Q34039305-5120293C-F888-4F85-9FA6-B01DB957EC37Q34799941-46756134-F4E4-4ECA-B5DE-6503D94B7133Q36245027-6E5F9814-52DD-42F6-9539-7B98F746DD55Q36800775-CD75994A-CDA2-4589-AA21-A80DEA0D8091Q37180671-CD2D194E-0B47-4604-AE05-3D78F47497D0Q37279146-E5625B63-1B5E-4340-8305-2480FFA5D329Q37512670-D40C13F6-04D6-4BFC-9633-82D98B7745A1Q37882879-74757FBE-1438-4344-ABA9-2C124B91EFC0Q37950427-65BEE99B-6DA6-42AD-A94C-26A1A3A6285DQ37996077-A4F4D36E-446F-4C84-85E8-0AEA37A00418Q38067297-01E6AB3D-9951-4F0C-9A06-4492AC160A2BQ38115004-70593012-9079-4896-9481-D4D02666A901Q38179453-FEF3B4D3-0659-4AD2-8558-CBE01451C81FQ38246682-F99DC2C0-91BB-444A-8A56-AD1ACB80E43EQ38261811-11B9B579-E9DC-46ED-BB29-87822C31A080Q38972042-627B827D-3BA6-4243-978B-3BDB673CF6B8Q39681299-1E6804BA-7539-4E67-B284-C4FB3E59E9BFQ42112507-6610AF4F-92AD-4949-8DF3-71BE0A587B3FQ43073052-96FF55DB-4918-4EFC-BEB1-2966864915B3Q43076967-321EAB80-20EF-4E2A-A418-8A113C5D32D8Q43442012-1FAAEEF6-3FEF-4D5A-8A13-13BC05A998A8Q45760942-6B90E099-F5C1-4873-AB07-31AE70DF409FQ45772751-88ECAB56-C175-4CAA-8833-096CE62405E5Q46274205-1239C810-E2DE-4787-9F41-4278DF8919A9Q47658773-A65347EE-1948-4526-A7BF-CFB2406640F5Q47741923-6AE1FBF0-3F02-4A52-A0B6-D4089ADCBFF7Q48192033-953D91C4-DC6D-405D-99F2-0A4D6F8AF436Q48209111-C9A3E97F-EE44-4694-ADE2-92C3CCDBF5CBQ48296756-6BF5EB81-429B-4E1C-B922-DF7EB6B23E17Q48636523-92453929-F8C0-44DC-9F1C-75318088CAB8Q49064482-2E9C0E83-41F6-4DBD-AF2C-E4709D1DD4A1Q50573804-461ECF99-3758-4EFC-BE11-1B463C156746Q51792730-48DDDF6D-4D47-4417-A5BE-8CA6805D8840Q57369531-9B313CDA-B083-4691-98EA-F9EF6D5BDC68Q57709593-57D06B0F-9170-4D00-9B4C-545ADAFF2CF9Q58700061-0E653161-DF39-42F5-AB4B-39538D2BC2AEQ59021200-965F0049-A03B-41E2-8023-FD409A123024
P2860
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@en
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@nl
type
label
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@en
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@nl
prefLabel
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@en
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@nl
P2093
P1476
Comprehensive review of rasagi ...... atment of Parkinson's disease.
@en
P2093
David M Swope
Jack J Chen
Khashayar Dashtipour
P304
P356
10.1016/J.CLINTHERA.2007.09.021
P577
2007-09-01T00:00:00Z